Progress in the Application of Exosomes in Androgenetic Alopecia: Focusing on Molecular Mechanisms
- Journal
- International journal of nanomedicine (Q1)
- Published
- 3 August 2026
- Study design
- Narrative review / expert opinion
- Evidence level
- Level 5, Expert Opinion (CEBM 5)
- Authors
- Yuanyuan Chen, Shuting Chen, Wei Ding, Ling Li, Peizhen Li, Zonghui Li, et al.
- PMID
- 42571418
- DOI
- 10.2147/IJN.S619230
Why clinicians should know about it
- Picked for Dermatology (paper of the day, 10 August 2026): Review of exosome therapy mechanisms for androgenetic alopecia
Abstract
Androgenetic alopecia (AGA) is the most common type of hair loss worldwide, characterized by progressive miniaturization of hair follicles and a shortened anagen phase. Currently, FDA-approved drugs for AGA treatment, minoxidil and finasteride, cannot provide satisfactory outcomes for all patients and can sometimes cause side effects. Therefore, there has been an urgent need for novel and safer therapeutic strategies. At the cellular and molecular level, the pathogenesis of AGA is closely associated with the dysregulation of signaling pathways in hair follicles. As nano-sized extracellular vesicles secreted by cells, exosomes carry bioactive substances such as proteins, lipids, and nucleic acids, thereby playing a crucial role in intercellular and intracellular communication. By modulating dysregulated signaling pathways in hair follicles, exosome therapy offers a highly promising therapeutic option for AGA patients. However, it should be noted that current evidence remains limited, and more well-designed studies are required to validate the long-term efficacy and safety of exosome-based therapies for AGA. Also, addressing challenges in the production, application, and regulation of exosomes is indispensable for promoting the future clinical application of exosome-based therapies in AGA treatment. This review summarizes the preclinical and clinical progress in exosome-based therapies for AGA treatment, with a particular focus on their molecular mechanisms, especially their regulation of key signaling pathways involved in AGA pathogenesis, such as Wnt/β-catenin, Shh, TGF-β/Smad, PI3K/AKT, and MAPK signaling pathways. These endeavors are expected to provide researchers with valuable scientific insights and practical information for AGA drug discovery.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.